<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819856</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-3005-501</org_study_id>
    <nct_id>NCT02819856</nct_id>
  </id_info>
  <brief_title>SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity</brief_title>
  <official_title>A PHASE 1b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS and PHARMACODYNAMICS OF SPI-1005 in CYSTIC FIBROSIS (CF) PATIENTS WITH ACTIVE PULMONARY EXACERBATION RECEIVING IV TOBRAMYCIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and tolerability of SPI-1005
      treatment in CF patients with active pulmonary exacerbation that are receiving an IV course
      of tobramycin, using histories, physical exams, vital signs (VS), adverse event (AE)
      reporting, hematology (CBC) chemistry (Chem-20).

      The secondary objectives of this study are to determine the pharmacokinetics of oral SPI-1005
      at 200, 400 and 600 mg BID for 21 days. Peak/trough assessments will be determined for
      ebselen, its major metabolite and selenium. Clinical assessments of the severity of
      sensorineural hearing loss, speech discrimination, vertigo severity, tinnitus severity and
      lung function will be made compared between treatment arms and the placebo arm of this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, dose-escalating, safety, PK, and PD study of
      oral SPI-1005 in CF patients with active pulmonary exacerbation about to receive a 21-day
      course of IV tobramycin (10 mg/kg/d). All patients will undergo baseline testing and have
      their severity of lung function, sensorineural hearing loss, tinnitus and vertigo determined
      before the start of SPI-1005 treatment. SPI-1005 treatment will start within first two days
      of IV tobramycin treatment and be administered concomitantly. At the end of the 21-day course
      of SPI-1005 and 28 days following the cessation of SPI-1005, patients will have their hearing
      loss, tinnitus and vertigo reassessed. Assessments may also include additional audiometric
      and pulmonary testing, and additional follow-up testing.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>7 weeks</time_frame>
    <description>The primary objective of this study is to evaluate the safety and tolerability of SPI-1005 at three different dose levels (200mg, 400mg, and 600mg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of sensorineural hearing loss</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in hearing thresholds using pure-tone audiometry with extended high frequency testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech discrimination</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change in Words in noise test (WINT) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinnitus severity</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in Tinnitus Functional Index (TFI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertigo severity</measure>
    <time_frame>7 weeks</time_frame>
    <description>vertigo symptom scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lung function</measure>
    <time_frame>7 weeks</time_frame>
    <description>Evaluation of lung function using FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Level of SPI-1005 at 200, 400, and 600 mg Ebselen po bid x 21d</measure>
    <time_frame>7 weeks</time_frame>
    <description>Plasma ebselen and major metabolite quantified in plasma by LC-MS/MS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ototoxicity</condition>
  <arm_group>
    <arm_group_label>SPI-1000 Capsule 0mg Ebselen Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0mg Ebselen SPI-1000 bid po x 21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg SPI-1005 bid po x 21d Low Dose Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg SPI-1005 bid po x 21d Mid Dose Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg SPI-1005 bid po x 21d High Dose Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1000 Capsule 0mg Ebselen Placebo</arm_group_label>
    <other_name>SPI-1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x1</intervention_name>
    <description>200 mg SPI-1005 bid po x21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x1</arm_group_label>
    <other_name>SPI-1005 Low Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x2</intervention_name>
    <description>400 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x2</arm_group_label>
    <other_name>SPI-1005 Mid Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x3</intervention_name>
    <description>600 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x3</arm_group_label>
    <other_name>SPI-1005 High Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients about to receive IV tobramycin for acute pulmonary
             exacerbation.

          -  Voluntarily consent to participate in the study.

          -  Females of childbearing potential should be using and committed to continue using one
             of the following acceptable birth control methods:

          -  Sexual abstinence (inactivity) for 14 days prior to screening through study
             completion; or IUD in place for at least 3 months prior to study through study
             completion; or Barrier method (condom or diaphragm) with spermicide for at least 14
             days prior to screening through study completion; or Stable hormonal contraceptive for
             at least 3 months prior to study through study completion.

          -  Ability to perform all behavioral tests as indicated.

        Exclusion Criteria:

          -  Current use or within 60 days prior to study enrollment the following IV ototoxic
             medications: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin,
             streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin,
             oxaliplatin); or loop diuretic (furosemide).

          -  History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular
             schwannoma.

          -  History of middle ear or inner ear surgery.

          -  Current conductive hearing loss or middle ear effusion.

          -  Significant cardiovascular, hepatic, renal, hematologic, endocrine, immunologic, or
             psychiatric disease.

          -  History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen.

          -  Participation in another investigational drug or device study within 30 days prior to
             study enrollment.

          -  Female patients who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>SOUND PHARMACEUTICALS, INC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Takumida M, Popa R, Anniko M. Free radicals in the guinea pig inner ear following gentamicin exposure. ORL J Otorhinolaryngol Relat Spec. 1999 Mar-Apr;61(2):63-70.</citation>
    <PMID>10095194</PMID>
  </reference>
  <reference>
    <citation>Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. Epub 2006 Oct 6.</citation>
    <PMID>17030476</PMID>
  </reference>
  <reference>
    <citation>Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3. Review.</citation>
    <PMID>19729669</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

